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Background: Over the last decade, the prevalence of obesity (BMI≥ 25 kg/m2) in Thailand has been rising rapidly and
consistently. Estimating the cost of obesity to society is an essential step in setting priorities for research and resource
use and helping improve public awareness of the negative economic impacts of obesity. This prevalence-based,
cost-of-illness study aims to estimate the economic costs of obesity in Thailand.
Methods: The estimated costs in this study included health care cost, cost of productivity loss due to premature
mortality, and cost of productivity loss due to hospital-related absenteeism. The Obesity-Attributable Fraction
(OAF) was used to estimate the extent to which the co-morbidities were attributable to obesity. The health
care cost of obesity was further estimated by multiplying the number of patients in each disease category
attributable to obesity by the unit cost of treatment. The cost of productivity loss was calculated using the
human capital approach.
Results: The health care cost attributable to obesity was estimated at 5,584 million baht or 1.5% of national
health expenditure. The cost of productivity loss attributable to obesity was estimated at 6,558 million
baht - accounting for 54% of the total cost of obesity. The cost of hospital-related absenteeism was estimated at
694 million baht, while the cost of premature mortality was estimated at 5,864 million baht. The total cost of
obesity was then estimated at 12,142 million baht (725.3 million US$PPP, 16.74 baht =1 US$PPP accounting for
0.13% of Thailand’s Gross Domestic Product (GDP).
Conclusions: Obesity imposes a substantial economic burden on Thai society especially in term of health care
costs. Large-scale comprehensive interventions focused on improving public awareness of the cost of and problems
associated with obesity and promoting a healthy lifestyle should be regarded as a public health priority.
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Obesity (defined as having a Body Mass Index (BMI)
greater than or equal to 30 Kilogram (Kg)/Meter(M)2) [1],
is a growing health concern worldwide. It is a known risk
factor for a number of chronic diseases including cardio-
vascular diseases, diabetes, musculoskeletal disorders, and
some cancers [2-5]. Aside from increased morbidity, obes-
ity has also been found to increase premature mortality* Correspondence: montarat.tha@mahidol.ac.th
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distribution, and reproduction in any medium[6-8], decrease productivity due to absenteeism and pres-
enteeism [9], and decrease quality of life [10-13].
As a result of increasing global urbanisation, changes in
dietary habits, and declining levels of physical activity, the
obesity epidemic is no longer limited to populations in
Europe and North America [14-17]. Today, it affects pop-
ulations in most countries, including those in Latin Amer-
ica and Asia. According to the World Health Organisation
(WHO), the global prevalence of obesity has more than
doubled between 1980 and 2008 [18]. In 2008, the WHO
estimated that more than 1.4 billion adults aged 20 and
over were overweight (a BMI greater than or equal to 25
Kg/M2) [18]. Of these overweight adults, 500 million were
obese [18].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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to one estimate from a recent systematic review, the
health costs associated with obesity may account for be-
tween 0.7% and 2.8% of a country’s total health care ex-
penditure [19]. In another review of data from ten
Western European countries, estimated obesity costs
were found to be as high as 0.09% to 0.61% of Gross
Domestic Product (GDP) [20]. Estimating the cost of
obesity to society is critical for policy makers, public
health planners, and other health stakeholders. Not
only can the cost estimate be used to establish prior-
ities for research and health resource use, but it can
also be used to improve public awareness of the nega-
tive economic impacts of obesity. In the past, many at-
tempts have been made to estimate the economic cost
of obesity in western countries [21-24]; few studies of
this kind were conducted in Asia. However, in light of
the rapid and continuous increase in obesity preva-
lence, several countries in Asia including Korea [25],
Taiwan [26], China [27], and Hong Kong [28] have
begun to assess the economic cost of obesity.
In line with global trends, the prevalence of obesity
in Thailand almost doubled between 1991 and 2009.
According to the fourth National Health Examination
Survey (NHES) 2008-9 [29], 28.4% of adult Thai men
and 40.1% of women were classified as obese (BMI ≥
25 Kg/M2). More importantly, the NHES also found
that obesity levels had risen disproportionately in rural
areas [30], indicating that obesity was no longer only
found in higher socioeconomic groups. Despite this
rapid increase in obesity over the last ten years, no re-
search has yet been conducted into the economic cost
of obesity in Thailand. Our study aims to estimate the
economic costs of obesity in Thailand, 2009.
Methods
This is a prevalence-based, cost-of-illness study. Costs
included in the analyses were health care cost, cost of
productivity loss due to premature mortality, and cost of
productivity loss due to hospital-related absenteeism.
Obesity and co-morbidities
In this study, obesity is defined as having a BMI of
25 Kg/m2 or higher. To estimate the cost associated with
obesity, a number of co-morbidities were identified and
their respective costs calculated. Based on the degree of
association with obesity, the availability of existing infor-
mation and its importance in the Thai context, the follow-
ing 12 co-morbidities were selected in our study: colon
and colorectal cancer, breast cancer, endometrial cancer,
hyperlipidemia, diabetes mellitus, depression, hyperten-
sion, ischemic heart disease, pulmonary embolism, stroke,
gall bladder disease, and osteoarthritis. For each co-
morbidity, the Obesity Attributable Fraction (OAF), theproportion of the incidence of a co-morbidity in the popu-












i = Body Mass Index (BMI) level (i = 1 means BMI ≥
25.0-29.9 kg/m2 and i = 2 means BMI ≥ 30 kg/m2)
j = Co-morbidity related to obesity (j = 1 -12)
Pi = Prevalence of obesity at BMI level i
RRij = Relative Risk of co-morbidity j associated with
obesity level i compared with the non-obese population
In this study, obesity prevalence (Pi) was obtained
from the 4th NHES [17] while the Relative Risks (RRij)
were derived from meta-analyses [32-34] as well as stud-
ies conducted in Asia [26,35].
Health care cost
The health care costs of obesity and the 12 co-morbidities
were estimated for both inpatient and outpatient services.
For each co-morbidity, the inpatient and outpatient
healthcare costs attributable to obesity were calculated by
multiplying the total number of patients with the given
co-morbidity in Thailand by the corresponding OAF, and
the average cost of each co-morbidity per person per year.
Each co-morbidity total was then added together to give a
total healthcare cost for obesity.
The outpatient data on the total number of patients and
the data on the cost of outpatient visit(s) for each co-
morbidity per person per year in 2009 were obtained from
the database of the Center for Health Equity Monitoring
(CHEM), Faculty of Medicine, Naresuan University. This
database includes outpatient information covered by the
two major public health insurance schemes in Thailand—
the Universal Coverage Scheme (UCS) and the Civil Med-
ical Service Scheme (CSMBS)—from 675 out of 843 public
hospitals (80%) across all 76 provinces throughout the
country. These two public health schemes cover approxi-
mately 80% of the total Thai population (approximately 67
million); the remaining 20% are covered by the Social Se-
curity Scheme (SSS), which is offered to formal private
sector employees. To estimate the total number of out-
patient visits in Thailand in 2009, it was assumed that 64%
of total outpatient visits in Thailand would be those cov-
ered by the CHEM database.
The inpatient data on the total number of patients and
the data on the cost of inpatient visit(s) for each co-
morbidity per person per year were obtained from the
Central Office for Health care Information (COHI)
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from all public hospitals for patients covered by the UCS
and CSMBS (but not the SSS). It was assumed that the
COHI data would represent 80% of total inpatients in
Thailand.
Cost of productivity loss due to premature mortality
The costs associated with productivity loss due to prema-
ture mortality were calculated for each co-morbidity using
the human capital approach. The number of deaths that
could be attributed to obesity in 2009, disaggregated by age
and gender, were multiplied by the average wage each per-
son would receive if he or she lived through his or her life-
span. A discount rate of 3% was employed [29]. The data
on the total number of deaths from each co-morbidity were
obtained from the 2004 Thai Burden of Disease (BOD)
project, and data on average earnings were calculated from
the 2009 National Economic and Social Survey.
Cost of productivity loss due to hospital related absenteeism
The cost of hospital-related absenteeism was also calcu-
lated using the human capital approach. To estimate the
cost of productivity loss due to hospital related absentee-
ism, the number of days that inpatients and outpatients
with obesity-related conditions were absent from work
in 2009 as a result of their obesity was multiplied by the
average daily wage. Outpatient absentee data was ob-
tained from the CHEM database; inpatient absentee data
was obtained from the COHI database. The calculation
was based on the assumption that the average outpatient
visit took 0.5 days. The average daily wage was calcu-
lated by dividing Thailand’s 2009 GDP per capita [36] by
the number of working days in the same year.
Results
The overall relative risk estimates and OAFs for obesity
and the 12 co-morbidities, disaggregated by gender, are
presented in Table 1. OAF estimates indicate that about
24% to 52% of all cases of diabetes mellitus, 25% to 33%
of all cases of ischemic heart disease, and 15% to 23% of
all cases of osteoarthritis in Thailand are attributable to
obesity, respectively.
Estimates of the overall economic costs of obesity, dis-
aggregated by types of cost, gender, and co-morbidity
are displayed in Table 2. With regard to total cost, the
three conditions that are found to incur the highest
costs are diabetes mellitus (6,385.7 million baht), ische-
mic heart disease (2,168.4 million baht), and stroke
(2,017.6 million baht).
As shown in Table 2, the estimated health care cost at-
tributable to obesity is 5,584 million baht. Obesity-related
health care costs for women are about 2.5 times higher
than for men (4,015 million baht VS 1,569 million baht).
The three conditions that incur the highest health carecosts are diabetes mellitus (3,386.6 million baht), ischemic
heart disease (1,070.6 million baht), and colorectal cancer
(377.3 million baht).
The estimated cost of premature mortality as a result
of obesity-related conditions is 5,864 million baht. The
premature mortality costs incurred by men are 1.5 times
higher than they are in women (3,531 million baht VS
2,333 million baht). The three conditions that incur the
highest premature mortality costs are diabetes mellitus
(2,550.2 million baht), stroke (1,800.6 million baht), and
ischemic heart disease (1,034.9 million baht).
The estimated cost of productivity loss due to absentee-
ism as a result of obesity-related conditions is 694 million
baht. Of this total, 448.8 million baht results from diabetes
mellitus, 102.3 million baht from hypertension, and 62.8
million baht from ischemic heart disease.
A summary of all of the estimated costs attributable to
obesity is presented in Table 3. The total estimated eco-
nomic cost of obesity in Thailand is 12,142.1 million baht
(725.3 million US$PPP, 16.74 baht =1 US$PPP [36] or
0.13% of GDP [36]. Health care costs account for 46% of
the total cost or about 1.5% of the national health care ex-
penditure [37], while productivity loss costs account for
56% of the total cost.
Discussion
Many studies have shown that obesity exerts a significant
cost burden on a country’s health system and productivity
[19,20]. This was also found in this first analysis of obesity
cost in the Thai context, where obesity-attributable costs
were found to be substantial, accounting for 0.13% of
GDP or 1.5% of the total national health expenditure. In
addition, the analysis revealed that costs associated with
heath care provision and costs associated with productiv-
ity loss were broadly similar, which are in line with the
findings of previous studies [22,38,39]. The cost identified
in this paper should be regarded as a minimum estimate
since other related costs such as the cost of absenteeism
not related to hospitalization, cost of presenteeism, and
unemployment costs were not included in the analysis.
Furthermore, due to the unavailability of data in Thailand,
the cost of premature mortality due to obesity and the fol-
lowing five co-morbidities—gall bladder disease, obesity,
hyperlipidemia, pulmonary embolism, and depression—
were not included in the analysis.
A WHO report [18] found that, globally, obesity and
overweight account for 23% of coronary heart disease
cases, 7-14% of cancer cases, and 44% of diabetes mellitus
cases. These general proportions were also found in our
analysis, which suggested that about 25-33% of ischemic
heart cases, 2% of breast cancer cases, 17% of endometrial
cancer cases, 8-9% of colon cancer cases, and 24-52% of
diabetes mellitus cases in Thailand were associated with
obesity. Unlike in Western countries [21-23], our study
Table 1 Relative risks for selected co-morbidities in obese subjects and Obesity Attributable Fraction (OAF)
Diseases/conditions Relative risk of developing diseases Obesity attributable fraction (OAF) (%)
Male Female Male Female
1* 2** 1* 2**
Breast cancer [32] - - 1.08 1.13 - 2
Colon and colorectal cancer [32] 1.51 1.95 1.45 1.66 8 9
Depression [32] 1.30 1.31 0.98 1.67 4 3
Diabetes mellitus [32] 2.40 6.47 3.92 12.41 24 52
Endometrial cancer [32] - - 1.53 3.22 - 17
Gall bladder [32] 1.09 1.43 1.44 2.32 2 12
Hyperlipidemia [26] 1.95 1.76 1.95 1.76 11 15
Hypertension [32] 1.28 1.84 1.65 2.42 5 15
Ischemic heart disease [35] 3.02 4.37 3.02 4.37 25 33
Obesity 1.00 1.00 1.00 1.00 100 100
Osteoarthritis [32] 2.76 4.20 1.80 1.96 23 15
Pulmonary embolism [32] 1.91 3.51 1.91 3.51 15 22
Stroke [32] 1.23 1.51 1.15 1.49 4 5
*1 = BMI25.0-29.9 kg/m2 **2 = BMI ≥ 30 kg/m2.
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the primary leading cause of economic burden. In line
with a previous study in Asia [25], and giving weight to re-
cent concerns that have been voiced regarding the epi-
demic of obesity and type 2 diabetes in Asia [16], we
found diabetes mellitus to be the first leading cause of
obesity cost (6,385.7 million baht), followed by ischemic
heart disease (2,168.4 million baht), and stroke (2017.6
million baht). Nevertheless, previous studies indicateTable 2 Estimates of the economic costs of obesity in Thailan
Disease Health care cost
(Million baht)
Cost of premature
mortality (Million baht) ho
Male Female Male Female
Diabetes mellitus 663.8 2,722.8 1,302.6 1,247.6
Ischemic heart disease 521.5 549.1 761.6 273.3
Stroke 98.9 99.6 1,236.1 564.5
Colon and rectal cancer 188.0 189.3 203.5 119.0
Hypertension 31.4 146.4 26.5 26.1
Osteoarthritis 46.3 113.6 0.7 0.6
Gall bladder 11.5 101.0 - -
Endometrial cancer - 42.3 - 2.8
Breast cancer - 36.6 - 99.3
Obesity 3.8 4.6 - -
Hyperlipidemia 0.9 2.1 - -
Pulmonary embolism 1.8 5.9 - -
Depression 0.8 1.8 - -
Total 1,568.7 4,015.1 3,531.0 2,333.2[40,41] that reducing weight by 5–10% can improve blood
sugar control and help reduce the risk of developing car-
diovascular disease. Given the rise of obesity in Asia, and
the prevalence of related conditions—particularly diabetes
mellitus and cardiovascular disease [16]—interventions
aimed at obesity control clearly deserve more attention.
In line with findings from previous studies in the US
[6,42,43], which found that obesity had a health impact
equal or exceeding that of smoking and drinking, ourd 2009 by types of costs, gender, and co-morbidity
Cost of productivity loss due to
spital-related absenteeism (Million baht)
Total cost
(Million baht)
Male Female Male Female All
88.1 360.7 2,054.5 4,331.2 6,385.7
29.6 33.2 1,312.7 855.7 2,168.4
9.2 9.4 1,344.1 673.5 2,017.6
6.0 6.3 397.4 314.7 712.1
18.6 83.7 76.5 256.2 332.7
8.2 17.6 55.2 131.8 187
1.1 8.9 12.6 109.9 122.5
- 2.5 0 47.6 47.6
- 1.7 0 137.6 137.6
1.2 2.5 5.0 7.1 12.1
1.1 2.5 2.0 4.6 6.6
0.1 0.5 1.9 6.5 8.4
0.4 0.7 1.3 2.5 3.8
163.6 530.2 5,263.2 6,878.9 12,142.1
Table 3 Summary of the estimated economic costs of
obesity in Thailand 2009
Cost Million baht %
Direct cost (health care cost) 5,584 46
OPD 850
IPD 4,734
Indirect cost (productivity loss) 6,558 54
Premature mortality 5,864
Hospital-related absenteeism 694
Total cost 12,142 100
% of total cost in term of GDP 0.13
% of Health care cost in term
of National health care expenditure [37]
1.5
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ity are the same as those attributable to alcohol consump-
tion, which was estimated at 5,491 million baht in 2006
[44]. Despite this, the numbers of public health campaigns
targeting obesity are fewer than those related to smoking
and drinking. One explanation may be that obesity and
the condition of being overweight are perceived as per-
sonal issues rather than social problems. However, our
findings clearly show that the effect of obesity on the
country’s economy is significant, especially in terms of
health care costs, which are currently shouldered by all
tax payers in Thailand. It is clear that, to effectively tackle
obesity in Thailand, a public health campaign targeting
obesity epidemic should place emphasis on the impact of
obesity on society as well as social responsibility without
stigmatising those who are obese.
In this study, BMI was used as a measure to determine
the prevalence of obesity. According to the WHO [45], a
BMI reading of 25-29.9 kg/m2 is indicative of an over-
weight condition, while a reading of 30 kg/m2 or higher
indicates obesity. However, in Asia, the risk of type 2
diabetes mellitus and cardiovascular disease is already
high in those whose BMI is below 25 kg/m2. In addition,
at the same BMI, Asian populations are found to have
higher levels of body fat than Western populations
[46,47]. Therefore, it has been proposed that lower BMI
readings should be used to identify those who are over-
weight or obese in the Asian population. A 2004 WHO
expert consultation proposed that an appropriate cut off to
measure the condition of being overweight and obese in
Asian populations would be 23-24.9 kg/m2 and 25 kg/m2,
respectively [47]. To permit comparison across previous
studies in estimating the economic cost of obesity, a BMI
reading of at least 25 kg/m2 was used to define obesity in
our study. Nevertheless, it should be noted that the esti-
mate impact of obesity will be lower if a BMI reading of
30 kg/m2 is used to define obesity.In this study, the prevalence of obesity in 2009 was
used to calculate the OAF. The estimated prevalence
constitutes people with a varied time period of obesity.
As induction times for chronic diseases may differ across
persons and diseases and are not exactly known, we
might have overestimated the cost from the impact of
obesity as the lapse time need for developing comorbid-
ity as well as duration of obesity were not taken into ac-
count. Nevertheless, these figures do inform at what cost
the societal inevitably need to shoulder in the future
without effective interventions to mitigate the current
burden of obesity. In addition, the identification of in-
duction times for chronic diseases is a priority area for
future research related to obesity.
Another limitation that warrants further discussion is
the reliance on estimated costs. While we acknowledge
that the validity of our findings relies on the accuracy of
a number of estimated parameters and assumptions, we
are confident that the estimates are reasonably accurate.
For instance, the CHEM and COHI databases (which
were used to estimate health care costs) are the largest
hospital databases available in Thailand. Nevertheless,
we assumed that the COHI accounted for 80% of all in-
patients in the country. However, based on the recent
figures [48], patients in COHI database may account for
83% of the total population. Therefore, our results might
slightly overestimate the impact of obesity. In addition,
while these databases only include data from patients
who are covered by the UCS and CSMBS schemes, we
assume that obesity prevalence among beneficiaries of
these two schemes will be comparable to those of the SSS.
We acknowledge, however that this assumption may be
somewhat limited as the SSS scheme covers those who are
healthy enough to be employed in the private sector; this
may mean that they suffer from lower levels of obesity. If
this is the case, then the total cost of obesity would be
somewhat lower than what we have estimated in this
study. Lastly, since there was no Thai-specific relative risk
data available, the relative risk data were obtained from
meta-analysis review of global literature, including a num-
ber of Asian studies [26,32-35]. Future research on relative
risk in Thailand, particularly for diabetes and cardiovascu-
lar disease, would be beneficial.Conclusions
This study confirmed that obesity imposes a substantial
economic burden on Thai society. In terms of health
care cost, it is equivalent to that imposed by alcohol
consumption. In light of the rapid and continuous in-
crease in obesity prevalence in Thailand, large-scale
comprehensive interventions for the prevention and
control of obesity should be regarded as of public health
priority in Thailand.
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